Rheumatoid Arthritis

Seropositivity was strongly associated with ILD risk in this large prospective cohort study.

The following medications were decreased most frequently and also associated with the greatest impact in terms of reduction of annual cost: adalimumab, etanercept, and rituximab.

Five questions to test your knowledge of the prevalence, risk, and classification of RA.

The Mediterranean diet may reduce the risk of rheumatoid arthritis in seropositive men.

Rheumatoid arthritis and juvenile idiopathic arthritis put pregnant women at risk for preterm delivery.

A potential pathway for treatment and a way to assess the prognosis of patients with rheumatoid arthritis.

CV risk reduction, pain catastrophizing, inept apps, and 5 other notable developments in RA research and clinical care.

Since current treat-to-target practice relies on disease activity measured at a single point in time, electronic patient-reported outcome measures (e-PROMs) represent a potentially powerful tool for monitoring patient disease activity between office visits.

One caveat: because several risk estimates reached higher confidence intervals, a clinically meaningful risk cannot be completely ruled out.

Is vitamin D supplementation warranted in patients at risk for rheumatoid arthritis?

Patients with rheumatic diseases should limit their participation in physical activity. True or false?

Test your knowledge of RA comorbidities with this short quiz.

At 12 weeks, patients with rheumatoid arthritis receiving filgotinib responded and achieved low disease activity at significantly higher rates compared to placebo.

Does the obesity paradox suggest a protective effect?

Where there’s smoke, there’s an increased risk of rheumatoid arthritis.

Foods that promote inflammation can raise the risk of seropositive RA in younger women but not in those older than age 55.

What underlies the apparent disparities in disease course and treatment outcomes between men and women with rheumatoid arthritis?

This dietary pattern has already been shown to reduce overall mortality, cardiovascular disease, and cancer. Do the benefits extend to RA?

Here: 6 key beliefs patients hold about DMARDs that drive their reluctance to continue therapy.

Which clinical and psychosocial factors have been implicated in a lack of response to MTX?

What constellation of symptoms points to the diagnosis?

The challenge: to distinguish patients at risk for progression to RA from those who have non-rheumatic arthritis.

Inflammation may underlie the link between major depressive disorder and RA.

Are you up for a little challenge? Test your diagnostic acumen with these 5 questions.

How exposure to vapor, gas, dust, and fumes can contribute to the progression of RA.